Medtronic plans MiniMed split-off exchange offer
Medtronic plc (MDT) states that it intends to split off its remaining ownership in MiniMed through an exchange offer, as the next step in separating MiniMed into a standalone, fully independent company.
Rhea-AI Filing Summary
Medtronic plc (MDT) states that it intends to split off its remaining ownership in MiniMed through an exchange offer, as the next step in separating MiniMed into a standalone, fully independent company. This follows MiniMed’s initial public offering on March 6 and is described as another milestone in that separation process.
The communication emphasizes that the exchange offer will be made solely by the prospectus included in MiniMed’s registration statement on Form S-4 and related documents, and that none of Medtronic, MiniMed, their directors or officers, or the dealer managers are recommending whether holders should participate. It also includes extensive forward-looking statements language outlining risks and uncertainties and urges investors and security holders to read the prospectus, Schedule TO, and other SEC filings before making any investment decision.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Key Figures
MiniMed initial public offering date: March 6
Information agent toll-free number: (877) 361-7972
Information agent non-U.S. contact number: (646) 845-0146
3 metrics
MiniMed initial public offering date
March 6
Date of MiniMed’s IPO referenced as the prior milestone before the exchange offer
Information agent toll-free number
(877) 361-7972
Toll-free phone number for Medtronic shareholders to contact D.F. King & Co., Inc. about the exchange offer
Information agent non-U.S. contact number
(646) 845-0146
Phone number for banks, brokers and others outside the United States to contact D.F. King & Co., Inc.
Key Terms
exchange offer, registration statement on Form S-4, Schedule TO, prospectus, +1 more
5 terms
exchange offer financial
"intention to split off our remaining ownership in MiniMed shares through an exchange offer"
An exchange offer is a proposal where a company asks investors to swap existing securities, like bonds or shares, for new ones, often with different terms or maturity dates. It matters to investors because it can affect the value of their holdings and the company's financial strategy, potentially providing benefits like better interest rates or reduced debt.
registration statement on Form S-4 regulatory
"MiniMed has filed with the SEC a registration statement on Form S-4"
A registration statement on Form S-4 is a formal filing with the U.S. Securities and Exchange Commission used when a company issues shares or other securities as part of a merger, acquisition, exchange offer or similar corporate deal. It bundles the transaction terms, financial statements, risk factors and shareholder vote materials so investors can assess the deal; think of it as a detailed prospectus or buyer’s packet that explains what you would own and how the deal could change your stake.
Schedule TO regulatory
"Medtronic has filed with the SEC a Schedule TO, which contains important information"
A phrase indicating that a company plans or intends to hold an event, publish information, or take an action at a specified future time, but that the timing is not guaranteed and may change. For investors it signals an expected milestone—like an earnings call, product launch, or filing—so think of it as a calendar note rather than a firm promise; timing shifts can affect trading, expectations, and planning.
prospectus financial
"The exchange offer is made solely by the prospectus"
A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.
information agent financial
"Medtronic has retained D.F. King & Co., Inc. as the information agent"
An information agent is a person, team, or third-party service designated to collect, verify and distribute a company’s important announcements, filings or notices to regulators, shareholders and the public. Think of it as the company’s official mailroom and translator combined—responsible for making sure the right facts get to the right people quickly and accurately; investors watch who serves this role because mistakes or delays can affect compliance, market reaction and trust.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What action is Medtronic (MDT) taking regarding its ownership in MiniMed?
Medtronic intends to split off its remaining ownership in MiniMed through an exchange offer, as a further step toward making MiniMed a standalone, fully independent company following its initial public offering on March 6.
How does the MiniMed exchange offer fit into Medtronic’s (MDT) separation plan?
The exchange offer is described as the next step in the process of separating MiniMed from Medtronic. It follows MiniMed’s IPO on March 6 and is framed as another important milestone toward MiniMed operating as an independent publicly traded company.
What cautions does Medtronic (MDT) provide about forward-looking statements in the MiniMed separation?
Medtronic notes that statements about the expected effects, timing and benefits of the exchange offer and separation are forward-looking and subject to risks, including regulatory, competitive, economic and execution risks described in Form 10-K, Form 10-Q, the Form S-4 registration statement, and Schedule TO.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed by Medtronic plc
pursuant to rule 425 under the Securities Act of 1933, as amended
Subject Company: Medtronic plc
Commission File No.: 1-36820
VP Vitals
To all Medtronic Vice Presidents and above
Executive level summary: Today Medtronic announced our intention to split off MiniMed shares through an exchange offer.
To all Medtronic Vice Presidents and above
Executive level summary: Today Medtronic announced our intention to split off MiniMed shares through an exchange offer.
Call to action: Review details about this announcement.
Confidentiality: Medium. All-company message to be distributed later.
Medtronic Vice Presidents,
As a next step in the process of separating MiniMed into a standalone business, today Medtronic announced our intention to split off our remaining ownership in MiniMed shares through an exchange offer (including any related transactions). This follows MiniMed’s initial public offering on March 6 and marks another milestone toward MiniMed becoming a fully independent company.
For your visibility, a preview of the all-employee email that explains this milestone and the actions open to employees can be found below. This message will be sent around 9 a.m. CT today.
Congratulations to our MiniMed colleagues on this next important step forward and thank you to all Medtronic teams who helped make this milestone possible.
/s/ Geoff Martha
Geoff Martha
Chairman and CEO
Chairman and CEO
+++++++++++++++++++++++++++++++++++++++++++++++++++++++
[Link: Email to All Global Medtronic Employees, Re: MiniMed share exchange offer notice]
Cautions Regarding Forward Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the expected effects on Medtronic and MiniMed of the exchange offer, the anticipated timing and benefits of the exchange offer, Medtronic’s ability to satisfy the necessary conditions to consummate its separation of MiniMed, Medtronic’s ability to successfully consummate the separation of MiniMed and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders for U.S. federal income tax purposes), MiniMed’s ability to
succeed as an independent publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in Medtronic’s and MiniMed’s periodic reports on file with the Securities and Exchange Commission (the “SEC”) including their most recent respective Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, the Registration Statement referred to below, including the prospectus forming a part thereof, the Schedule TO, and other exchange offer documents filed by Medtronic or MiniMed, as applicable, with the SEC. In some cases, you can identify these statements by forward-looking words or expressions, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “going to,” “will,” and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this communication, including to reflect future events or circumstances.
Additional Information and Where to Find It
This communication is for informational purposes only and is not an offer to sell or exchange, a solicitation of an offer to buy or exchange any securities or a recommendation as to whether investors should participate in the exchange offer. MiniMed has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”) that includes a prospectus. The exchange offer is made solely by the prospectus. The prospectus contains important information about the exchange offer, Medtronic, MiniMed and related matters, and Medtronic has delivered the prospectus to holders of Medtronic ordinary shares. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROSPECTUS, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BEFORE MAKING ANY INVESTMENT DECISION, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. None of Medtronic, MiniMed or any of their respective directors or officers or the dealer managers appointed with respect to the exchange offer make any recommendation as to whether you should participate in the exchange offer.
Medtronic has filed with the SEC a Schedule TO, which contains important information about the exchange offer.
Holders of Medtronic ordinary shares may obtain copies of the prospectus, the Registration Statement, the Schedule TO and other related documents, and any other information that Medtronic and MiniMed file electronically with the SEC free of charge at the SEC’s website at http://www.sec.gov. Holders of Medtronic ordinary shares may also obtain a copy of the prospectus by clicking on the appropriate link on http://www.dfking.com/MDTSeparation.
Medtronic has retained D.F. King & Co., Inc. as the information agent for the exchange offer. To obtain copies of the prospectus and related documents, or for questions about the terms of the exchange offer or how to participate, you may contact the information agent at (877) 361-7972 (toll-free for shareholders) or (646) 845-0146 (banks, brokers and all others outside the United States).